Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Alnylam Pharmaceuticals, Inc. (ALNY) - free report >>
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Alnylam Pharmaceuticals, Inc. (ALNY) - free report >>
Image: Bigstock
Best Momentum Stocks to Buy for January 21st
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 21st:
CareDx, Inc (CDNA - Free Report) : This diagnostic solutions company for transplant patients and caregivers has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.5% over the last 60 days.
CareDx, Inc. Price and Consensus
CareDx, Inc. price-consensus-chart | CareDx, Inc. Quote
CareDx’s shares gained 13.6% over the last six months compared with the S&P 500’s advance of 7.7%. The company possesses a Momentum Score of A.
CareDx, Inc. Price
CareDx, Inc. price | CareDx, Inc. Quote
Anavex Life Sciences Corp. (AVXL - Free Report) : This clinical stage biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.8% over the last 60 days.
Anavex Life Sciences Corp. Price and Consensus
Anavex Life Sciences Corp. price-consensus-chart | Anavex Life Sciences Corp. Quote
Anavex’s shares gained 63.3% over the last three months compared with the S&P 500’s advance of 2.4%. The company possesses a Momentum Score of A.
Anavex Life Sciences Corp. Price
Anavex Life Sciences Corp. price | Anavex Life Sciences Corp. Quote
Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 20.4% over the last 60 days.
Alnylam Pharmaceuticals, Inc. Price and Consensus
Alnylam Pharmaceuticals, Inc. price-consensus-chart | Alnylam Pharmaceuticals, Inc. Quote
Alnylam’s shares gained 1.6% over the past month compared with the S&P 500’s advance of 0.4%. The company possesses a Momentum Score of A.
Alnylam Pharmaceuticals, Inc. Price
Alnylam Pharmaceuticals, Inc. price | Alnylam Pharmaceuticals, Inc. Quote
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.